Home » Newsletters » BioWorld

BioWorld

April 7, 1994

View Archived Issues

IDUN LICENSES BCL-X GENE

ANERGEN'S MYASTHENIA GRAVIS PROGRAM MOVES FORWARD

DIAGNON PLANS CANCER-FOCUSED CORPORATION

ONCOGENE GETS BROAD PATENT

SMITHKLINE LICENSES CORLOPAM RIGHTS TO NEUREX

GERMANY, ITALY BAR SALESOF DDI DRUG

IMCLONE GETS CRC CANCER VACCINE RIGHTS

METASYN COMPLETES $4M PRIVATE PLACEMENT

TOP CLOT BUSTER GRADUATES FROM HEART TO LIMBS TO BRAIN

NEW THERAPY IMPROVES GENE EXPRESSION

ANGRY SHAREHOLDERS PROPOSE CHANGES AT SCIOS NOVA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 23, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
K2 nabs two Antengene bispecific TCEs in $2B license, option deal
BioWorld
MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene...
In the clinic for June 22, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...